AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a long-acting amylin analogue developed by Danish biotech Gubra.

Explore GUBRA A S by GUBRA A S stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for GUBRF. AbbVie partners with Gubra in a $2.2 billion deal to develop ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...

The pharma company announcing a license agreement with a company called Gubra for an obesity drug. Gubra is a Danish research company, will receive $350 million in upfront payments, up to $1.88 ...

Partnership marks AbbVie's entrance into the obesity field Agreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...

The deal includes a $350 million upfront payment to the company, Gubra, for the rights to its drug, called for now GUB014295. AbbVie will pay up to some $1.9 billion if certain development and ...

AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal ...

AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra. AbbVie said it will pay up to about $2.2 billion for the drug GUBamy, which is currently in a Phase 1 ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research ...

The outlay, plus up to $1.87 billion in milestones, has landed the drugmaker rights to a long-acting amylin analog that is in phase 1 development at Gubra. As a major player in the medical ...